Two technology companies are pursuing significant valuations in separate funding activities, highlighting continued investor interest in specialized sectors despite broader market conditions.

NewLimit, a longevity-focused biotechnology startup founded by Coinbase's Brian Armstrong, has reached a valuation of $3.1 billion, representing a threefold increase from its previous valuation. The company focuses on developing therapies aimed at extending human lifespan and improving health outcomes.

The startup plans to begin testing its RNA-based therapy in patients with alcohol-related liver disease next year, marking a key milestone in advancing its research from laboratory development to human trials. This represents the company's first major clinical application of its longevity-focused technology platform.

Separately, cybersecurity company Cyera is pursuing a $300 million funding round that would value the firm at approximately $12 billion. Evolution Equity Partners is reportedly leading this financing round, which would represent a significant increase in the company's valuation.

The proposed valuation represents roughly 80 times Cyera's annual recurring revenue, a notably high multiple that reflects both the premium investors place on cybersecurity companies and the competitive funding environment in the sector. However, the company is currently operating at a loss despite its revenue growth.

Both funding activities demonstrate continued investor appetite for companies in high-growth sectors, particularly those addressing significant market opportunities in healthcare technology and cybersecurity infrastructure.